Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
11/08/2022 - 04:05 PM
SAN DIEGO --(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Guggenheim 4th Annual Immunology and Neurology Day
November 14, 2022 in New York, NY
J.P. Morgan Equity Opportunities Forum
November 15, 2022 in Miami, FL
A live webcast of Acadia’s presentation at the Guggenheim conference at 9:35 a.m. Eastern Time on November 14, 2022 will be accessible on the company’s website, www.acadia.com , under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20221108006174/en/
Media Contact:
Acadia Pharmaceuticals Inc.
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson , CFA
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc
ACAD Rankings
#572 Ranked by Stock Gains
ACAD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About ACAD
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
